Do you want to visit this external website and leave amgenpro.com.au?
You are now leaving this Amgen Australia website. Amgen Australia assumes no responsibility for, and exercises no control over, the organizations, opinions, or accuracy of the information on the server or website you are redirected to.
Do you want to visit this external website and leave amgenpro.com.au?
You are now leaving this Amgen Australia website. Amgen Australia assumes no responsibility for, and exercises no control over, the organizations, opinions, or accuracy of the information on the server or website you are redirected to.
You can paste this link into an email or message to share this resource with your patient.
Lung cancer remains a significant oncological challenge in Australia, representing one of the leading causes of cancer morbidity and mortality. It is broadly classified into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), with the latter accounting for approximately 15% of cases. Learn more about SCLC, new targets such as Delta-like ligand 3, and the potential role of bi-specific T-cell engager molecules below.
AmgenPro is intended for healthcare professionals in Australia
Login or create an AmgenPro account to access the latest updates on our products, medical resources and patient programs.
AUS-757-26-80006 | May 2026